Jump to main content
Jump to site search

Issue 35, 2017
Previous Article Next Article

Biocompatible and blood–brain barrier permeable carbon dots for inhibition of Aβ fibrillation and toxicity, and BACE1 activity

Author affiliations

Abstract

Amyloid-β peptide (Aβ) fibrillation is pathologically associated with Alzheimer's disease (AD), and this has resulted in the development of an Aβ inhibitor which is essential for the treatment of AD. However, the design of potent agents which can target upstream secretases, inhibit Aβ toxicity and aggregation, as well as cross the blood–brain barrier remains challenging. In, this research carbon dots for AD treatment were investigated in vitro using experimental and computational methods for the first time. The results presented here demonstrate a novel strategy for the discovery of novel antiamyloidogenic agents for AD treatments.

Graphical abstract: Biocompatible and blood–brain barrier permeable carbon dots for inhibition of Aβ fibrillation and toxicity, and BACE1 activity

Back to tab navigation

Supplementary files

Publication details

The article was received on 16 Jun 2017, accepted on 07 Jul 2017 and first published on 12 Jul 2017


Article type: Communication
DOI: 10.1039/C7NR04352J
Citation: Nanoscale, 2017,9, 12862-12866
  •   Request permissions

    Biocompatible and blood–brain barrier permeable carbon dots for inhibition of Aβ fibrillation and toxicity, and BACE1 activity

    X. Han, Z. Jing, W. Wu, B. Zou, Z. Peng, P. Ren, A. Wikramanayake, Z. Lu and R. M. Leblanc, Nanoscale, 2017, 9, 12862
    DOI: 10.1039/C7NR04352J

Search articles by author

Spotlight

Advertisements